1.Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014;41:
90-111. doi: 10.1016/j.preteyeres.2014.03.003. [PubMed:24680929].
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections
for 2030. Diabetes Care. 2004;27(5):1047-53. [PubMed: 15111519].
3. Obrosova IG, Julius UA. Role for poly (ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and
retinopathy. Curr Vasc Pharmacol. 2005;3(3):267-83. [PubMed: 16026323].
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615. [PubMed:
15919781].
5. Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci.2007;48(8):3805-11. doi: 10.1167/iovs.06-1280. [PubMed:
17652755].
6. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603. doi:
10.1155/2007/43603. [PubMed: 17641741].
7. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and
treatment perspectives. Rev Endocr Metab Disord. 2008; 9(4):315-27. doi: 0.1007/s11154-008-9090-4. [PubMed:
18654858].
8. Riahi S, Mohammadi MT, Sobhani V, Ababzadeh S. Chronic aerobic exercise decreases lectin-like low density lipoprotein (LOX-1) receptor expression in heart of diabetic rat. Iran Biomed J. 2016;20(1):26-32. [PubMed: 26432573].
9. Coucha M, Elshaer SL, Eldahshan WS, Mysona BA, El-Remessy AB. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle East Afr J Ophthalmol. 2015; 22(2):135-44. doi: 10.4103/0974-9233.154386. [PubMed:25949069].10. Lai AK, Lo AC. Animal models of diabetic retinopathy:
Mojarrab S et al.48 Razavi Int J Med. 2018; 6(3):e46865. summary and comparison. J Diabetes Res. 2013;2013:106594.
doi: 10.1155/2013/106594. [PubMed: 24286086].
11. Kedziora‐Kornatowska K, Luciak M, Paszkowski J. Lipid peroxidation and activities of antioxidant enzymes in the
diabetic kidney: effect of treatment with angiotensin convertase inhibitors. IUBMB Life. 2000;49(4):303-7. doi:
10.1080/15216540050033177. [PubMed: 10995033].
12. Kowluru R, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or galactosemia II. Comparison of γglutamyl transpeptidase in retina and cerebral cortex, and effects of antioxidant therapy. Curr Eye Res. 1994;13(12):891-
6. [PubMed: 7720397].
13. Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV.
Antioxidant defense system. Free Radic Biol Med. 1996; 22(4):587-92. [PubMed: 9013121].
14. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008;101(10A): 58D-68D. doi: 10.1016/j.amjcard.2008.02.010. [PubMed:18474276].
15. Otton R, Marin DP, Bolin AP, Santos Rde C, Polotow TG, Sampaio SC, et al. Astaxanthin ameliorates the redox imbalance in lymphocytes of experimental diabetic rats. Chem Biol Interact. 2010;3(186):306-15. doi: 10.1016/j.cbi.2010.05.011. [PubMed: 20513374].
16. Leite MF, Lima AM, Massuyama MM, Otton R. Astaxanthin restores the enzymatic antioxidant profile in salivary gland of alloxan-induced diabetic rats. Arch Oral Biol. 2010;55(7):479-85. doi: 10.1016/j.archoralbio.2010.04.006. [PubMed: 20510163].
17. McNulty H, Jacob RF, Mason RP. Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am J Cardiol. 2008;10(101):20D-9D. doi: 10.1016/j.amjcard. 2008.02.004. [PubMed: 18474269].
18. Curek GD, Cort A, Yucel G, Demir N, Ozturk S, Elpek GO, et al. Effect of astaxanthin on hepatocellular injury following
ischemia/reperfusion. Toxicology. 2010;267(1-3):147-53. doi: 10.1016/j.tox.2009.11.003. [PubMed: 19900500].
19. Palozza P, Torelli C, Boninsegna A, Simone R, Catalano A, Mele MC, et al. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett. 2009;283(1):108. doi: 10.1016/j.canlet.2009.03.031. [PubMed: 19423215].
20. Cort A, Ozturk N, Akpinar D, Unal M, Yucel G, Ciftcioglu A, et al. Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure. Regul Toxicol Pharmacol. 2010;58(1):121-30. doi: 10.1016/j.yrtph.2010.05.001. [PubMed:20457203].
21. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae. Mol Nutr Food Res. 2011;55(1):150-65. doi: 10.1002/mnfr.201000414. [PubMed: 21207519].
22. Tso MO, Lam TT. Method of retarding and ameliorating central nervous system and eye damage. US Patent.1996;5:527-33.
23. Wolf A, Asoh S, Hiranuma H, Ohsawa I, Iio K, Satou A, et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J Nutr Biochem. 2010;21(5):381-9. doi: 10.1016/j.jnutbio.2009.01.011. [PubMed: 19423317]
24. Dong LY, Jin J, Lu G, Kang XL. Astaxanthin attenuates the apoptosis of retinal ganglion cells in db/db mice by inhibition of oxidative stress. Mar Drugs. 2013;11(3):960-74. doi: 10.3390/md11030960. [PubMed: 23519150].
25. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione:
applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502-22. [PubMed: 4388022].
26. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin
Med. 1975;85(2):337-41. [PubMed: 803541].
27. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta.
1978;90(1):37-43. [PubMed: 719890].
28. Kruger NJ. The Bradford method for protein quantitation. In: Walker JM, editor. The protein protocols handbook. New York: Humana Press; 2009. P. 17-24.
29. Santocono M, Zurria M, Berrettini M, Fedeli D, Falcioni G. Influence of astaxanthin, zeaxanthin and lutein on DNA
damage and repair in UVA-irradiated cells. J Photochem Photobiol B. 2006;85(3):205-15. doi: 10.1016/j.jphotobiol.
2006.07.009. [PubMed: 16962787].
30. Tiwari BK, Pandey KB, Abidi A, Rizvi SI. Markers of oxidative stress during diabetes mellitus. J Biomark. 2013;2013:378790. doi: 10.1155/2013/378790. [PubMed: 26317014].
31. Bandeira Sde M, Guedes Gda S, da Fonseca LJ, Pires AS, Gelain DP, Moreira JC, et al. Characterization of blood oxidative stress in type 2 diabetes mellitus patients: increase in lipid
peroxidation and SOD activity. Oxid Med Cell Longev. 2012;2012:819310. doi: 10.1155/2012/819310. [PubMed:
23259029].
32. Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm
Biotechnol. 2011;12(3):362-8. [PubMed: 20939798].
33. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis
and efflux. Diabetologia. 1995;38(2):201-10. [PubMed: 7713315].
34. Jackson H, Braun CL, Ernst H. The chemistry of novel xanthophyll carotenoids. Am J Cardio. 2008;101(10A):50D-57D. doi:10.1016/j.amjcard.2008.02.008. [PubMed: 18474275].
35. Marin DP, Bolin AP, Macedo Rde C, Sampaio SC, Otton R. Ros production in neutrophils from alloxan-induced diabetic rats treated in vivo with astaxanthin. Int Immunopharmacol. 2011;11(1):103-9. doi: 10.1016/j.intimp.2010.10.013. [PubMed:21055504].
36. Breithaupt DE. Modern application of xanthophylls in animal feeding-a review. Trends Food Sci Technol. 2007;18(10):501-6. doi: 10.1016/j.tifs.2007.04.009.
37. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84. doi: 10.1016/j.biocel.2006.07.001. [PubMed: 16978905].
)